Polaris News

22

Jan 16

Polaris Group Completes Construction of Its GMP Manufacturing Facility in China

SAN DIEGO, January 22, 2016 – Polaris Group announced today that its wholly owned subsidiary DesigneRx Pharmeceuticals (DRX) (Chengdu) has completed the building constructions of its GMP manufacturing facility for biological drugs in Chengdu, China. The construction broke ground in November 2013 and covers 11.3 acres in Chengdu High-tech Park....
Read More

5

Jan 16

Polaris Group Subsidiary Announces Expansion of cGMP Manufacturing Facility

VACAVILLE, CALIFORNIA, January 5, 2016 – Polaris Group today announced that its subsidiary DesigneRx Pharmaceuticals, Inc. (DRX) has completed construction of its new, expanded cGMP facility for manufacturing biological pharmaceuticals in Vacaville, California. The existing facility was built in 2004 and has been used to produce pharmaceutical products to support...
Read More

12

Oct 15

Polaris Group Acquires 100% Ownership of TDW Group

Taipei, October 12, 2015 – Polaris Group announced today that it has acquired ownership of all outstanding shares of TDW Group in a share exchange transaction. Prior to the acquisition, Polaris Group owned a 27% stake in TDW Group and following the acquisition, TDW Group became a wholly-owned subsidiary of...
Read More

25

Jun 15

Polaris Group’s Lead Therapeutic ADI-PEG 20 Shows Activity against Primary Acute Myeloid Leukemia

SAN DIEGO, June 25, 2015 – Polaris Group announced today that its lead therapeutic ADI-PEG 20 (pegylated arginine deiminase) was shown to have activity against primary acute myeloid leukemia (AML), both in vitro and in vivo, as reported in a research article published in the journal Blood. In addition, 28...
Read More

22

May 15

Additional Tumor Type Cohorts Added to the Ongoing Phase 1 Study Combining ADI-PEG 20 with Cisplatin and Pemetrexed Based on New Research Results

SAN DIEGO, May 22, 2015 – Polaris Group announced today that it has filed a protocol amendment with the FDA to include two additional dose expansion cohorts treating uveal melanoma and glioblastoma in its ongoing phase 1 study that tests its lead therapeutic ADI-PEG 20 (pegylated arginine deiminase) in combination...
Read More

22

Apr 15

Polaris Group’s ADI-PEG 20 Restores Cisplatin Sensitivity to Cisplatin-Resistant Non-Small Cell Lung Carcinoma Cells

SAN DIEGO, April 22, 2015 – Polaris Group announced today that its lead therapeutic ADI-PEG 20 (pegylated arginine deiminase) restored cisplatin sensitivity to multiple cisplatin-resistant (CR) non-small cell lung carcinoma (NSCLC) cell lines in vitro. The results were generated by two groups of collaborating researchers from University of Miami and...
Read More

3

Feb 15

Polaris Group Announces Treatment of First Patient in Phase 1 Study of ADI-PEG 20 plus FOLFOX in Advanced Gastrointestinal Malignancies

SAN DIEGO, February 3, 2015 – Polaris Group announced today that the first patient has been dosed in its Phase 1 trial of ADI-PEG 20 in combination with folinic acid (leucovorin), fluorouracil and oxaliplatin (FOLFOX) for the treatment of advanced gastrointestinal malignancies. In addition to a global Phase 3 study...
Read More

18

Dec 14

Polaris Group Lead Therapeutic Candidate ADI-PEG 20 Receives Orphan Drug Designation in the United States and the European Union for the Treatment of Malignant Pleural Mesothelioma

SAN DIEGO, December 18, 2014 – Polaris Group announced today that its lead product candidate ADI-PEG 20 (pegylated arginine deiminase) has received orphan drug designation for the treatment of malignant pleural mesothelioma (MPM) in the United States and in the European Union. Orphan drug designation grants special status to a...
Read More